ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

Claudio Luchini; Frédéric Bibeau; M. Ligtenberg; Naveena Singh; Alessia Nottegar; Tjalling Bosse; Robert E. Miller; Nadeem Riaz; J-Y Douillard; Fabrice André; Aldo Scarpa

doi:10.1093/annonc/mdz116

Abstract

This ESMO initiative is a response to the urgent questions raised by the growing success of immunotherapy and provides also important insights on the relationships between MSI, TMB and PD-1/PD-L1.

Keywords

Microsatellite instabilityMSH6MSH2MLH1DNA mismatch repairPMS2MedicineLynch syndromeComputational biologyCancerOncologyCancer researchMicrosatelliteBioinformaticsInternal medicineGeneticsBiologyColorectal cancerGene

Affiliated Institutions

Related Publications

Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy

Philip D. Dunne , Darragh G. McArt , Paul G. O’Reilly +9 more

Abstract A recent phase II study of patients with metastatic colorectal carcinoma showed that mismatch repair gene status was predictive of clinical response to PD-1–targeting i...

2016 Cancer Immunology Research 40 citations

Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.

Michael J. Overman , Sara Lonardi , Francesco Leone +16 more

519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair...

2017 Journal of Clinical Oncology 69 citations

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolás J. Llosa , Michael Cruise , Ada Tam +15 more

Abstract We examined the immune microenvironment of primary colorectal cancer using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry, and functional a...

2014 Cancer Discovery 1398 citations

Immunotherapy in colorectal cancer: rationale, challenges and potential

Karuna Ganesh , Zsofia K. Stadler , Andrea Cercek +4 more

Following initial successes in melanoma treatment, immunotherapy has rapidly become established as a major treatment modality for multiple types of solid cancers, including a su...

2019 Nature Reviews Gastroenterology & Hep... 1861 citations

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Timothy A. Chan , Mark Yarchoan , Elizabeth M. Jaffee +4 more

Abstract Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/...

2018 Annals of Oncology 2769 citations

Publication Info

Year: 2019
Type: review
Volume: 30
Issue: 8
Pages: 1232-1243
Citations: 990
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

990

OpenAlex

Cite This

APA Style

                            
                                
                                    Claudio Luchini, 
                                
                                    Frédéric Bibeau, 
                                
                                    M. Ligtenberg
                                
                                et al.
                            
                            (2019). 
                            ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. 
                            Annals of Oncology
                            , 30
                            (8)
                            , 1232-1243.
                            https://doi.org/10.1093/annonc/mdz116
                        

Identifiers

DOI: 10.1093/annonc/mdz116